Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02752074
Title A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Incyte Corporation
Indications
Therapies
Age Groups: adult
Covered Countries USA | SWE | POL | NZL | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BEL | AUS


No variant requirements are available.